ArticleBioinformation2026
Anemia correction using Roxadustat among MHD patients: 50mg versus 100mg dosing schedules.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a common complication in maintenance hemodialysis (MHD) patients. Hence, roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, was evaluated at two dosing schedules (50 mg versus 100 mg) in a randomized, open-label study of 65 patients. Both doses significantly increased hemoglobin and reduced red cell transfusion requirements over 12 weeks. The 100 mg dose produced a quicker and more pronounced response. Headaches were frequent but manageable and blood pressure remained stable. Roxadustat was well tolerated, supporting its role as a viable treatment option for anemia in dialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.